Search

An efficient copper-catalyzed, microwave-assisted, one-pot reaction has been developed for synthesis of 3,4-diaryl isoquinolines. The reaction was performed in two steps via a CuI/2,2′-biimidazole-catalyzed tandem process from N- tert-butyl- o-iodobenzaldimine and a terminal aryl alkyne, followed by addition of an aryl iodide. A variety of 3,4-diaryl isoquinolines have been obtained in moderate to good yields. [ABSTRACT FROM AUTHOR]

Thermal degradation of hydroxypropyl trimethyl ammonium chloride chitosan-Cd complexes (HTCC-Cd) was investigated by thermogravimetric analysis. The results indicate that the degradation of HTCC-Cd in nitrogen atmosphere was two-step reaction. For the first step of degradation, the initial temperature of mass loss ( T), the final temperature of mass loss ( T), and the temperature of maximum mass loss ( T) increase linearly with the rising of heating rate ( B). T = 1.241 B + 220.3, T = 1.111 B + 245.8, and T = 1.335 B + 358.2. Using different methods, the kinetic parameters of the two steps were investigated. The results show that the activation energies of the first step of degradation obtained using Friedman and Flynn-Wall-Ozawa methods are 1.684 × 10 and 1.646 × 10 J mol, and the corresponding activation energies for the second step are 1.165 × 10 J mol and 1.373 × 10 kJ mol. The results obtained from Phadnis-Deshpande methods indicate that the two degradation processes are both nucleation and growth process, and follow A mechanism with intergral form g( X) = [−ln(1 − X)]. [ABSTRACT FROM AUTHOR]

Objective: To examine the effectiveness and safety of two different B cell activating factor/proliferation-inducing ligand inhibitors, telitacicept and belimumab, in treating patients with active systemic lupus erythematosus (SLE).Patients with active SLE who received belimumab (n = 100) or telitacicept (n = 101) from 2019 to 2023 at multiple centers in China were retrospectively collected, and the effectiveness and safety of telitacicept and belimumab was evaluated. The subgroups of lupus nephritis and hematologic abnormalities were analyzed to explore if there were any differences in the efficacy of the two biologics on improving kidney and blood systems. Propensity score-based inverse probability of treatment weighting (IPTW) was used to reduce selection bias.No significant between-group differences in patient characteristics were observed after adjustment by IPTW. The proportion of SLE Responder Index 4 at 24 weeks was significantly higher in the telitacicept group (p = 0.031), but no significant difference was observed in 52 weeks follow-up data. More significant improvements were observed in telitacicept group for C4 and a larger decrease was observed in telitacicept group for IgA and IgM levels at 4 weeks. A better improvement of hemoglobin in anemia patients from the telitacicept group at 24 weeks was observed. There were no significant differences in kidney effectiveness and treatment-related adverse events differences between the two groups.Patients receiving telitacicept showed a higher SRI-4 rate compared to those receiving belimumab at 24 weeks. Due to the real-world nature of this study and the limitation of IPTW application, further extensive investigations in larger cohorts and head-to-head clinical trials are required to validate these findings.Key Points• The telitacicept group displayed a higher SRI-4 rate at 24 weeks and a more substantial improvement in serological indices at 4 weeks.• No differences were observed in the effectiveness in lupus nephritis patients between belimumab and telitacicept groups.• A better improvement of hemoglobin in anemia patients at 24 weeks was observed in telitacicept group.Key Points• The telitacicept group displayed a higher SRI-4 rate at 24 weeks and a more substantial improvement in serological indices at 4 weeks.• No differences were observed in the effectiveness in lupus nephritis patients between belimumab and telitacicept groups.• A better improvement of hemoglobin in anemia patients at 24 weeks was observed in telitacicept group.Methods: To examine the effectiveness and safety of two different B cell activating factor/proliferation-inducing ligand inhibitors, telitacicept and belimumab, in treating patients with active systemic lupus erythematosus (SLE).Patients with active SLE who received belimumab (n = 100) or telitacicept (n = 101) from 2019 to 2023 at multiple centers in China were retrospectively collected, and the effectiveness and safety of telitacicept and belimumab was evaluated. The subgroups of lupus nephritis and hematologic abnormalities were analyzed to explore if there were any differences in the efficacy of the two biologics on improving kidney and blood systems. Propensity score-based inverse probability of treatment weighting (IPTW) was used to reduce selection bias.No significant between-group differences in patient characteristics were observed after adjustment by IPTW. The proportion of SLE Responder Index 4 at 24 weeks was significantly higher in the telitacicept group (p = 0.031), but no significant difference was observed in 52 weeks follow-up data. More significant improvements were observed in telitacicept group for C4 and a larger decrease was observed in telitacicept group for IgA and IgM levels at 4 weeks. A better improvement of hemoglobin in anemia patients from the telitacicept group at 24 weeks was observed. There were no significant differences in kidney effectiveness and treatment-related adverse events differences between the two groups.Patients receiving telitacicept showed a higher SRI-4 rate compared to those receiving belimumab at 24 weeks. Due to the real-world nature of this study and the limitation of IPTW application, further extensive investigations in larger cohorts and head-to-head clinical trials are required to validate these findings.Key Points• The telitacicept group displayed a higher SRI-4 rate at 24 weeks and a more substantial improvement in serological indices at 4 weeks.• No differences were observed in the effectiveness in lupus nephritis patients between belimumab and telitacicept groups.• A better improvement of hemoglobin in anemia patients at 24 weeks was observed in telitacicept group.Key Points• The telitacicept group displayed a higher SRI-4 rate at 24 weeks and a more substantial improvement in serological indices at 4 weeks.• No differences were observed in the effectiveness in lupus nephritis patients between belimumab and telitacicept groups.• A better improvement of hemoglobin in anemia patients at 24 weeks was observed in telitacicept group.Results: To examine the effectiveness and safety of two different B cell activating factor/proliferation-inducing ligand inhibitors, telitacicept and belimumab, in treating patients with active systemic lupus erythematosus (SLE).Patients with active SLE who received belimumab (n = 100) or telitacicept (n = 101) from 2019 to 2023 at multiple centers in China were retrospectively collected, and the effectiveness and safety of telitacicept and belimumab was evaluated. The subgroups of lupus nephritis and hematologic abnormalities were analyzed to explore if there were any differences in the efficacy of the two biologics on improving kidney and blood systems. Propensity score-based inverse probability of treatment weighting (IPTW) was used to reduce selection bias.No significant between-group differences in patient characteristics were observed after adjustment by IPTW. The proportion of SLE Responder Index 4 at 24 weeks was significantly higher in the telitacicept group (p = 0.031), but no significant difference was observed in 52 weeks follow-up data. More significant improvements were observed in telitacicept group for C4 and a larger decrease was observed in telitacicept group for IgA and IgM levels at 4 weeks. A better improvement of hemoglobin in anemia patients from the telitacicept group at 24 weeks was observed. There were no significant differences in kidney effectiveness and treatment-related adverse events differences between the two groups.Patients receiving telitacicept showed a higher SRI-4 rate compared to those receiving belimumab at 24 weeks. Due to the real-world nature of this study and the limitation of IPTW application, further extensive investigations in larger cohorts and head-to-head clinical trials are required to validate these findings.Key Points• The telitacicept group displayed a higher SRI-4 rate at 24 weeks and a more substantial improvement in serological indices at 4 weeks.• No differences were observed in the effectiveness in lupus nephritis patients between belimumab and telitacicept groups.• A better improvement of hemoglobin in anemia patients at 24 weeks was observed in telitacicept group.Key Points• The telitacicept group displayed a higher SRI-4 rate at 24 weeks and a more substantial improvement in serological indices at 4 weeks.• No differences were observed in the effectiveness in lupus nephritis patients between belimumab and telitacicept groups.• A better improvement of hemoglobin in anemia patients at 24 weeks was observed in telitacicept group.Conclusions: To examine the effectiveness and safety of two different B cell activating factor/proliferation-inducing ligand inhibitors, telitacicept and belimumab, in treating patients with active systemic lupus erythematosus (SLE).Patients with active SLE who received belimumab (n = 100) or telitacicept (n = 101) from 2019 to 2023 at multiple centers in China were retrospectively collected, and the effectiveness and safety of telitacicept and belimumab was evaluated. The subgroups of lupus nephritis and hematologic abnormalities were analyzed to explore if there were any differences in the efficacy of the two biologics on improving kidney and blood systems. Propensity score-based inverse probability of treatment weighting (IPTW) was used to reduce selection bias.No significant between-group differences in patient characteristics were observed after adjustment by IPTW. The proportion of SLE Responder Index 4 at 24 weeks was significantly higher in the telitacicept group (p = 0.031), but no significant difference was observed in 52 weeks follow-up data. More significant improvements were observed in telitacicept group for C4 and a larger decrease was observed in telitacicept group for IgA and IgM levels at 4 weeks. A better improvement of hemoglobin in anemia patients from the telitacicept group at 24 weeks was observed. There were no significant differences in kidney effectiveness and treatment-related adverse events differences between the two groups.Patients receiving telitacicept showed a higher SRI-4 rate compared to those receiving belimumab at 24 weeks. Due to the real-world nature of this study and the limitation of IPTW application, further extensive investigations in larger cohorts and head-to-head clinical trials are required to validate these findings.Key Points• The telitacicept group displayed a higher SRI-4 rate at 24 weeks and a more substantial improvement in serological indices at 4 weeks.• No differences were observed in the effectiveness in lupus nephritis patients between belimumab and telitacicept groups.• A better improvement of hemoglobin in anemia patients at 24 weeks was observed in telitacicept group.Key Points• The telitacicept group displayed a higher SRI-4 rate at 24 weeks and a more substantial improvement in serological indices at 4 weeks.• No differences were observed in the effectiveness in lupus nephritis patients between belimumab and telitacicept groups.• A better improvement of hemoglobin in anemia patients at 24 weeks was observed in telitacicept group. [ABSTRACT FROM AUTHOR]